Cell Culture
l Poor reproducibility between batches of bio- mimetic scaffolds.
Tissue Creation
√ √
√ √ √ √ √
√
√ √
√ √
√ √
√ √
√ √ √
√ √
√
√ √ √ √
√
√ √ √ √
HCS imaging Plate reading
HCS imaging Services Cell supply Cell supply
3D Model Development
Stem Cell Focus
Other Features/ Applications:
l 3D matrices have too many components and creation of constructs is difficult and laborious.
l Limited ability to scale up or down a single 3D format.
l Post culturing processing/cell extraction from matrix difficult to handle.
l Virtual lack of proven automated solutions. l All methods need higher throughput. l Lack of methodology directly applicable to screening and bioprocessing.
l Wider applicability needed, today everything depends upon or is limited to the specific model.
l Lack of consistency between 3D cultures (espe- cially primary and stem cells).
Bioreactor, Cell supply
Cell supply HCS imaging
l Greater flexibility to accommodate the many different cell-lines and types.
l Better methods (readouts) for characterising cells cultured in these geometries.
l Better visualisation, wider applicability to HCS and video imaging, better image analysis tools.
l Room for improvement with more physiologi- cal substrates.
l Limited stability in long term experiments.
Prolonged culture, Cell harvesting
Services
In conclusion, the state-of-the-art seems to some way off from providing fully validated or robust 3D culture solutions and the field is clearly open to major improvements at this point in time. DDW
Bioreactor
Reference 1 3D Cell Culture Trends 2010 Report, published by HTStec Limited, Cambridge, UK, February 2010.
Bioreactor
the maintenance and expansion of stem cells and 3D is perceived as a way of manipulating this microenvironment. Also conditioned media derived from mesenchymal stem cells grown in 3D matrixes has instructive effects on the differentia- tion of some stem cells. Quite a number vendors highlighted in this review are developing and opti- mising their 3D offering to further stem cell research (ECACC, Global Cell Solutions, Glycosan, RegeneMed, Reinnervate, RealBio, Synthecon, The Automation Partnership). Reading the vendor snapshots one might con- clude that 3D cell culture was a done deal and tis- sue generation is readily achievable, however HTStec’s survey uncovered many problems and unmet needs, for example:
Drug Discovery World Summer 2010
Dr John Comley is Managing Director of HTStec Limited, an independent market research consul- tancy whose focus is on assisting clients delivering novel enabling platform technologies (liquid han- dling, laboratory automation, detection instrumen- tation and assay reagent technologies) to drug dis- covery and the life sciences. Since its formation seven years ago, HTStec has published more than 50 market reports on drug discovery technologies and Dr Comley has authored more than 30 review articles in Drug Discovery World. Please contact
info@htstec.com for more information.
41
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92